United States · Platforms & data · Finviz

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...

Published by Finviz · United States 14 h ago

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Phase 1b…

Read the full article on Finviz Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finviz.com)

Also worth reading

MarketBeat

‘It’s good to be old’: I’ve been invited to a dozen free meals that turn into annuity sales pitches. Should I stop going?

The Motley Fool

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

Investing.com

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...

Share

Also worth reading

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

Tech borrowers are picking up the tab: debt premium hits a 23-year high

Texas governor race tightens in prediction markets, but Abbott remains favored

‘It’s good to be old’: I’ve been invited to a dozen free meals that turn into annuity sales pitches. Should I stop going?

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

Treasury yields edge up as Election Day meets JOLTS, refunding